Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone

Haematologica. 2017 Apr;102(4):e120-e124. doi: 10.3324/haematol.2016.154740. Epub 2016 Dec 29.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Antigens, CD34 / genetics
  • Antigens, CD34 / immunology
  • Benzylamines
  • Cell Cycle Proteins / genetics
  • Cell Cycle Proteins / immunology
  • Chemokine CXCL12 / genetics*
  • Chemokine CXCL12 / immunology
  • Cyclams
  • Drug Combinations
  • Endonucleases / genetics
  • Endonucleases / immunology
  • Gene Expression Profiling
  • Gene Expression Regulation
  • Granulocyte Colony-Stimulating Factor / pharmacology*
  • Hematopoietic Stem Cell Mobilization / methods*
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cells / cytology
  • Hematopoietic Stem Cells / immunology
  • Heterocyclic Compounds / pharmacology*
  • Humans
  • Immunophenotyping
  • Leukapheresis
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / immunology
  • Mice
  • Protein Binding
  • Receptors, CXCR4 / genetics*
  • Receptors, CXCR4 / immunology
  • Signal Transduction
  • Stem Cell Niche / immunology*
  • beta-Thalassemia / genetics
  • beta-Thalassemia / immunology
  • beta-Thalassemia / pathology
  • beta-Thalassemia / therapy

Substances

  • Antigens, CD34
  • Benzylamines
  • CXCL12 protein, human
  • CXCR4 protein, human
  • Cell Cycle Proteins
  • Chemokine CXCL12
  • Cyclams
  • Drug Combinations
  • Heterocyclic Compounds
  • Receptors, CXCR4
  • Granulocyte Colony-Stimulating Factor
  • Endonucleases
  • plerixafor